Download Files:
Alpelisib
$60 – $790
Products Details
Product Description
– Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity[1][2][3].
Web ID
– HY-15244
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C19H22F3N5O2S
Citations
– Am J Cancer Res. 2021 Mar 1;11(3):773-792.|Biochem Biophys Res Commun. 2020 Sep 24;530(3):520-526.|Biomaterials. 16 September 2022.|Biomed Pharmacother. 2020 Sep;129:110397.|Biomed Rep. 2023 Oct 13.|Biomolecules. 2021 Jan 25;11(2):150.|bioRxiv. 2020 Jan.|bioRxiv. 2023 Aug 22.|bioRxiv. 2023 May 30.|Biosci Rep. 2020 Oct 30;40(10):BSR20201128.|Blood. 2019 Jan 3;133(1):70-80.|Br J Cancer. 2022 Nov 1.|Br J Haematol. 2020 May;189(4):731-744.|Breast Cancer Res. 2021 May 21;23(1):57.|Cancer Cell. 2023 Jun 12;41(6):1103-1117.e12.|Cancer Discov. 2020 Aug;10(8):1226-1239.|Cancer Discov. 2023 Aug 25;CD-23-0396.|Cancer Lett. 2019 Jan;440-441:54-63.|Cancer Nanotechnol. 2023 Mar 29.|Cancer Res. 2021 Mar 8;canres.3232.2020.|Cancers (Basel). 2022, 14(15), 3559.|Cell Biosci. 2022 Dec 30;12(1):210.|Cell Death Dis. 2020 Oct 6;11(10):831.|Cell Death Dis. 2022 Jan 12;13(1):54.|Cell Metab. 2021 Nov 2;33(11):2247-2259.e6.|Cell Rep. 2020 Sep 29;32(13):108196.|Cell Syst. 2018 Apr 25;6(4):424-443.e7.|Cell Syst. 2019 Jul 24;9(1):35-48.e5. |Cell Syst. 2020 Jan 22;10(1):66-81.e11.|Cells. 2022, 11(15), 2402.|Endocrinology. 2023 Sep 13;bqad135.|Front Oncol. 2021 Jul 13;11:704042.|Gynecol Oncol. 2020 Dec;159(3):827-838.|Harvard Medical School LINCS LIBRARY|Int J Mol Sci. 2023 Aug 30, 24(17), 13418.|Int J Mol Sci. 2019 Jul 10;20(14):3383. |Int J Oncol. 2022 Apr;60(4):37.|J Anal Sci Technol. 13, 31 (2022).|J Clin Invest. 2021 Dec 15;131(24):e140436.|J Exp Med. 2023 Nov 6;220(11):e20211743.|J Exp Med. 2023 Nov 6;220(11):e20230926.|J Hematol Oncol. 2020 Feb 22;13(1):13.|J Proteome Res. 2021 Apr 26.|J Transl Med. 2022 Jun 7;20(1):263.|JCI Insight. 2022 Jul 19;e155899.|Mol Cancer Res. 2020 Jun;18(6):822-834.|Mol Psychiatry. 2021 Apr 30.|Molecules. 2020 Apr 23;25(8):1980.|Nat Biomed Eng. 2018 Aug;2(8):578-588.|Nat Commun. 2020 Aug 13;11(1):4053.|Nat Commun. 2022 Jan 11;13(1):245.|Nat Commun. 2023 Jul 13;14(1):4084.|Nature Aging. 2023 Jan 23.|Nature Cancer. 2021 Jan;2(1):34-48.|Nature. 2018 Jun;558(7711):540-546. |Neoplasia. 2023 Jun 20;43:100913.|Oncogene. 2016 Jul 7;35(27):3607-12. |Oncol Rep. 2019 Nov;42(5):2097-2107.|Patent. US20220249511A1.|Patent. US20220313694A1.|Proc Natl Acad Sci U S A. 2022 Nov 16;119(46):e2215621119.|Research Square Preprint. 2020 Aug.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2023 May 10.|Research Square Preprint. 2023 May 9.|Sci Adv. 2022 Dec 9;8(49):eade7823.|Sci Rep. 2021 Jan 11;11(1):291.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Sci Transl Med. 2021 Oct 6;13(614):eabg0809.|Science. 2017 Dec 1;358(6367):eaan4368.|Science. 2021 Oct;374(6563):eabf3067.|STAR Protoc. 2023 Nov 16;4(4):102683.|Ther Adv Med Oncol. 2020 Dec 14;12:1758835920975621.|Cancers (Basel). 2022, 14(1), 214.
References
– [1]Gobin B, et al. BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer. 2015 Feb 15;136(4):784-96.|[2]Fritsch C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014 May;13(5):1117-29.|[3]Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8.
CAS Number
– 1217486-61-7
Molecular Weight
– 441.47
Compound Purity
– 99.95
SMILES
– CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 83.33 mg/mL (ultrasonic)
Target
– PI3K
Isoform
– PI3Kα;PI3Kβ;PI3Kγ;PI3Kδ
Pathway
– PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
